Form 4: Day One Biopharmaceuticals Director Natalie Holles Granted Significant Equity Awards

Day One Biopharmaceuticals, Inc. Director Natalie C. Holles was granted 22,500 stock options and 15,000 deferred restricted stock units on June 2, 2025, as reported in a recent SEC Form 4 filing.

Summary

• Natalie C. Holles, a Director of Day One Biopharmaceuticals, Inc. (DAWN), acquired 22,500 stock options and 15,000 deferred Restricted Stock Units (RSUs) on June 2, 2025.
• The stock options have an exercise price of $7.01 per share and will vest at a rate of 1/12th of the total grant on each monthly anniversary, commencing July 2, 2025, contingent on her continued service.
• Each RSU represents a contingent right to receive one share of the company's Common Stock upon settlement for no consideration.
• The RSUs will vest 100% on the earlier of June 2, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• Upon vesting, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for an equal number of common shares by the earlier of calendar year 2030 or Ms. Holles' separation from the Issuer, with provisions for earlier settlement under specific circumstances like death, disability, or an unforeseeable emergency.

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is a positive sign of alignment and retention, but does not contain new operational or financial news that would significantly alter sentiment beyond this standard practice.

Positives

• The grant of stock options and RSUs to Director Natalie C. Holles aligns her interests with long-term shareholder value, as these awards are performance-based and vest over time.
• The deferred settlement of RSUs until 2030 or separation indicates a commitment to long-term retention of key board members.

Future Outlook

The equity grants to Director Holles indicate a long-term commitment to her role and align her incentives with the company's future performance, particularly through the multi-year vesting schedules for both stock options and RSUs.

Industry Context

Equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize top talent, aligning their interests with long-term shareholder value creation, especially given the long development cycles inherent in the sector.

Comparison to Industry Standards

• The structure of the equity grants, including stock options with a multi-year vesting schedule and RSUs with a deferred settlement, is consistent with common compensation practices for directors in publicly traded biotechnology companies.
• While specific comparable companies or projects are not mentioned in this filing, such grants are typical for companies like Day One Biopharmaceuticals (DAWN) that rely on long-term strategic leadership.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value creation, as the awards vest over time and are tied to the company's stock performance.
• Employees: While not directly impacting general employees, the compensation structure for directors can set a precedent for executive compensation practices within the company.

Next Steps

• Continued service of Natalie C. Holles to Day One Biopharmaceuticals, Inc. for the vesting of her stock options and RSUs.
• Monthly vesting of 1/12th of stock options beginning July 2, 2025.
• Vesting of RSUs on the earlier of June 2, 2026, or the 2026 annual meeting of stockholders.
• Conversion of vested RSUs into deferred stock units.
• Settlement of deferred stock units into common shares by 2030 or upon separation.

Key Dates

Recommendation

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership